In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression

• US 9,983,212 B2
• Filed: 05/02/2014
• Issued: 05/29/2018
• Est. Priority Date: 05/03/2013
• Status: Active Grant

• Current Assignee: Salion GmbH
• Original Assignee: Salion GmbH
• Inventors: Abendroth, Dietmar, Stangl, Manfred J, Marzinzig, Michael
• Primary Examiner(s): COUNTS, GARY W
• Application Number:
  US14/888,729
• Publication Number:
  US 20160084843A1
• Time in Patent Office: 1,488 Days
• Field of Search: None
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 2800/7076 Amino acid metabolism
• CPC Class Codes: G01N 2800/7095 Inflammation
• CPC Class Codes: G01N 33/64 involving ketones
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems.

Claims

1. A method for the early detection of a potential inflammation in a patient caused by a rejection of a transplant before any clinical symptoms occur, comprising:

obtaining a saliva sample from the patient after receiving a transplant but prior to the patient recognizing any clinical symptoms of a transplant rejection;

measuring the level of one or more kynurenine metabolites selected from the group consisting of L-kynurenine, kynurenic acid, 3-hydroxy-L-kynurenine and combinations thereof in the saliva sample by a competitive assay utilizing kynurenine-specific antibodies;

diagnosing the patient with a transplant rejection when said kynurenine level in the saliva sample of the patient is from about 2 μ

M/L to about 7 μ

M/L; and

administering immunosuppressive graft-saving therapy to the diagnosed patient.

2. The method of claim 1 wherein the potential inflammation is caused by the rejection of a transplant organ selected from the group comprising liver, pancreas, heart, lung and kidney.

3. The method of claim 1 wherein the potential inflammation is caused by a transplant selected from the group comprising cornea-transplants, retina-transplants, cartilage-transplants and skin-transplants.

4. The method of claim 1 wherein the potential inflammation is caused by the rejection of an artificial transplant.

5. The method of claim 4 wherein the artificial transplant is selected from the group comprising bone replacements, joint replacements, tooth implants, cartilage implants, breast implants and penis implants.

9. The method of claim 1, wherein the method is utilized for monitoring the recovery of a patient after having received a transplant.

10. The method of claim 1, wherein the method is utilized for controlling therapy in a patient after having received a transplant.

6. A method for the early detection of a potential inflammation in a patient caused by a rejection of a transplant before any clinical symptoms occur, comprising:

obtaining a saliva sample from the patient after receiving a transplant but prior to the patient recognizing any clinical symptoms of a transplant rejection;

removing components from said saliva sample which may disturb the correct test result wherein said components comprise N-formyl kynurenine;

measuring the level of one or more kynurenine metabolites selected from the group consisting of L-kynurenine, kynurenic acid, 3-hydroxy-L-kynurenine and combinations thereof in said saliva sample by a competitive assay utilizing kynurenine-specific antibodies;

diagnosing the patient with a transplant rejection when said kynurenine level in the saliva sample of the patient is from about 2 μ

M/L to about 7 μ

M/L; and

administering immunosuppressive graft-saving therapy to the diagnosed patient.

7. The method of claim 6, wherein the disturbing components of the saliva sample are removed by precipitation followed by centrifugation.

8. The method of claim 6, wherein the disturbing components of the saliva sample are removed by deproteinization followed by centrifugation.